Antibodies against epitopes in S1 give the most accurate CoP against infection by the SARS‐
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …

Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …

Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an
important component of the comprehensive response to the severe acute respiratory …

Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

Background Early intramuscular administration of SARS-CoV-2-neutralising monoclonal
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …

The severe acute respiratory syndrome coronavirus 2 Omicron BA. 1 sublineage has been
supplanted in many countries by the BA. 2 sublineage. BA. 2 differs from BA. 1 by about 21 …

The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the
globe. This new variant of concern carries an unusually high number of mutations in key …

Summary Background The Solidarity trial among COVID-19 inpatients has previously
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …

Convergent evolution of SARS-CoV-2 Omicron BA. 2, BA. 4, and BA. 5 lineages has led to
the emergence of several new subvariants, including BA. 2.75. 2, BA. 4.6. and BQ. 1.1. The …

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …